Navigation Links
Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Date:3/30/2011

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The ATOMIC trial is designed to explore 12 and 24 week durations of PSI-7977. The potency, high barrier to resistance, and consistent antiviral activity across genotypes provided the data to support an interferon free dosing period in this trial, as well as enabling us to enroll multiple genotypes in this trial."  

About the Phase 2b ATOMIC Trial

This Phase 2b trial is planned to enroll approximately 300 patients with chronic HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the safety and tolerability of PSI-7977 in combination with peginterferon and ribavirin over 12 or 24 weeks. The trial will be conducted in the U.S. Patients will be randomized (1:2:3) into the following arms:

  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 24 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks, followed by either PSI-7977 400mg QD monotherapy for 12 weeks or PSI-7977 400mg QD plus ribavirin for 12 weeks.

HCV GT1 patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. An additional 25 treatment-naïve patients w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Webcast an Investor Event From the EASL Meeting
2. Pharmasset to Present at Three Upcoming Investor Conferences
3. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
4. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
5. Pharmasset Announces Exercise of Underwriters Overallotment Option
6. Pharmasset Prices Public Offering of Common Stock
7. Pharmasset Announces Proposed Public Offering of Common Stock
8. Pharmasset Reports Positive Results from its HCV Clinical Programs
9. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In accordance with Rule 17.1 and Rule 2.9 ... United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") ... (NYSE: ELN). Background On 2 May ... for the entire of the issued and to be issued ... On 20 May 2013, Royalty Pharma announced ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... , May 24, 2013 3SBio ... the "Company"), a leading China ... and marketing biopharmaceutical products, announced today that, at ... the Company,s shareholders voted in favor of the ... agreement and plan of merger dated February 8, ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... a clinico-molecular informatics company, today announced the commercialization ... lines that translate patient-specific molecular and genomic data, ... more effective drug choices for patients. ... drastically and clinical data becoming increasingly accessible, today,s ...
... /PR Newswire-Asia/ -- Global Pharm Holdings Group, Inc. ... growing vertically integrated pharmaceutical company engaged in the ... processing, and herbal cultivation and sales in China ... Shandong provinces, today announced the appointment of Mr. ...
Cached Medicine Technology:MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 2MolecularHealth to Introduce Knowledge-Driven Solutions that Enhance Drug Safety and Enable Molecularly-Guided Treatment Decision Support 3Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:5/25/2013)... California (PRWEB) May 25, 2013 While ... honoring those who have died serving our Country, many ... with prolonged partying and recklessness. The DUI attorneys at ... Weekend DUI checklist to help keep this weekend’s party-goers ... Records System , there were more than 950 fatal ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Life ... which are used to detect and create a new ... test reading and are also known as biotechnology reagents. ... bioscience, diagnosis and education. , This market is driven ... reagents in the field of therapeutics, growth in research ...
(Date:5/25/2013)... May 25 (HealthDay News) -- Many viruses and parasites ... and leptospirosis -- a bacteria-borne illness than can result ... at dog parks, according to a veterinarian. ... and even the air, said Dr. Susan Nelson, a ... Center. "Many of these serious diseases can be fatal, ...
(Date:5/25/2013)... Studies from Johns Hopkins University reveal a ... and their inability to get adequate sleep. These same ... naturally relieve many symptoms. , Johns Hopkins University ... was significantly associated with overall weight loss, especially belly ... November 6th, 2012, researchers monitored 77 participants who were ...
(Date:5/25/2013)... Pradaxa lawsuits filed on ... internal bleeding while using the blood thinner continue to mount ... District of Illinois, Bernstein Liebhard LLP reports. According to ... claims had been filed in the litigation as ... reported by the Court on May 15th. ( In Re: ...
Breaking Medicine News(10 mins):Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 2Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 3Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3
... of orphaned youth age 12 to 24 who head households ... report in the August issue of Archives of Pediatrics ... The combined effects of the 1994 genocide and the HIV ... in the worldan estimated 290,000 in 2005, according to background ...
... patient went home , , MONDAY, Sept. 1 (HealthDay News) ... in rehabilitation have less functional recovery, new research shows. ... published in the Sept. 1 issue of Sleep ... of recovery (e.g., mental status, hours of therapy received, ...
... Komen for the Cure(R), the,leader of the global ... G. Komen for the Cure Advocacy Alliance, are ... National Convention,about breast self awareness and to advocate ... uninsured and underinsured., (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ), ...
... WASHINGTON, Sept. 1 /PRNewswire-USNewswire/-- Service Employees,International Union (SEIU) ... RN, issued the following statement regarding the work,being ... country in anticipation of,the health impacts of Hurricane ... the Gulf Coast, leaders of the Nurse,Alliance of ...
... mandatory evacuations and the,approaching Hurricane Gustav, Pacer ... Louisiana medical facilities: South Cameron Memorial,Hospital (Cameron, ... LA). Effective immediately, both facilities will cease ... local and state officials.,Facility patients have been ...
... those unable to take ACE inhibitors , , SUNDAY, Aug. ... possible alternative to heart patients and diabetics who need ... cannot tolerate the standard treatment of ACE inhibitors. , ... on Sunday, Canadian researchers said they found that the ...
Cached Medicine News:Health News:Depression common among Rwandan youth who head households 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2Health News:Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues 2Health News:Nurse Alliance of SEIU Healthcare Mobilizing RNs and Medical Supplies to Gulf Coast Areas in Advance of Hurricane Gustav 2Health News:South Cameron Memorial Hospital and Calcasieu Oaks Psychiatric Hospital Discontinue Operations as Result of Impending Hurricane Gustav 2Health News:Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics 2
The OneTouch Flexx Professional Blood Glucose Monitoring System with OneTouchPro Test Strips sets the standard for safety and convenience with unique off-meter sample application and a wide range of ...
... the market in New Technology, the Arrow ... whole new first and only IABP system ... a physiologically based timing algorithm, WAVE, to ... accuracy. Second generation Automaticity provides for ...
... NEXES Special Stains automated system ... to provide enhanced consistency of ... stains. Proprietary kinetic technology, including ... Mixing, assures high quality routine ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
Medicine Products: